United States Acute On Chronic Liver Failure (ACLF) Market 2025 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

Global Acute on Chronic Liver Failure market is growing at a CAGR of 6% during the forecast period 2024-2031.

Recent Mergers and acquisitions:

✅ In October 2025, Roche completed the acquisition of 89bio for up to USD 3.5 billion to strengthen its portfolio in liver and metabolic diseases. While primarily focused on MASH, the acquisition enhances Roche's long-term capabilities in liver-regeneration therapeutics, potentially extending to ACLF treatment development.

✅ In October 2025, Novo Nordisk acquired Akero Therapeutics for approximately USD 5.2 billion, gaining access to a late-stage investigational drug targeting advanced liver disorders. The acquisition supports Novo Nordisk's strategy to expand its footprint in liver-disease therapeutics, including potential ACLF applications.

✅ In 2025, Genfit Biopharma entered a licensing agreement with Seal Rock Therapeutics to acquire rights to the candidate SRT-015, targeting ACLF and related acute liver conditions. The deal included potential milestone payments of up to EUR 100 million, reinforcing Genfit's leadership in the ACLF domain.

✅ In September 2022, Genfit acquired Versantis, a Swiss biotech specializing in acute liver failure therapeutics, for approximately USD 116 million. This acquisition significantly broadened Genfit's liver-disease pipeline and established its position in ACLF treatment development.

Japan: Recent Mergers & Acquisitions

✅ In September 2025, Takeda Pharmaceutical Company announced a partnership with a U.S.-based biotech firm to co-develop regenerative liver therapies, with a focus on acute and chronic liver failure applications. The collaboration aims to accelerate clinical translation of advanced biologics for ACLF management.

✅ In August 2025, Otsuka Holdings completed a strategic investment in a European liver therapeutics startup working on bioengineered hepatocyte technology. The investment expands Otsuka's research scope in acute liver dysfunction and transplantation alternatives.

✅ In July 2025, Astellas Pharma formed a research alliance with Kobe University Hospital to evaluate novel cell-based therapies for ACLF and decompensated cirrhosis. The partnership supports Japan's national initiative on regenerative medicine in end-stage liver disease.

✅ In June 2025, Eisai Co., Ltd. announced a technology acquisition from a domestic biotech startup focused on exosome-based liver regeneration therapies. The deal aims to strengthen Eisai's regenerative-medicine pipeline for liver failure, including ACLF and NASH-related indications.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/acute-on-chronic-liver-failure-aclf-market?sb

Key Development:

United States: Recent Industry Developments

✅ In April 2025, eGenesis and OrganOx Ltd. announced that the U.S. Food & Drug Administration (FDA) approved an investigational new drug (IND) application for EGEN-5784 - a genetically engineered porcine liver graft intended to support patients with Acute-on-Chronic Liver Failure (ACLF) in intensive-care settings.

✅ In February 2025, Genfit Biopharma revealed it expects Phase II results later in the year from its UNVEIL-IT trial of VS-01 in ACLF, and noted the FDA has granted Orphan Drug Designation for VS-01 in ACLF.

✅ In February 2025, a competitive-landscape report indicated that there are 71 trials initiated over the past decade for ACLF in the U.S., yet currently no therapies approved and no candidate confirmed in late-stage (Phase III/pre-registration) development.

Japan: Recent Industry Developments

✅ A Japanese clinical trial registry lists a dose-finding Phase 2 study (ID jRCT2061240059) of GSK4532990 for adult alcohol-related liver disease (ALD) registered Oct 2024 and still recruiting (Japan) indicating movement in adjacent liver-failure areas

✅ A pipeline commentary from early 2025 highlights that a number of global ACLF programmes intend to include Japanese sites or seek regulatory engagement in Japan, though no Japan‐specific ACLF announcement with exact date was found.

✅ The competitive-landscape report (Feb 2025) also covers Japan, noting that globally ~71,713 incident ACLF cases were estimated in 2024 and projected to rise; Japan is part of that footprint, though therapy development remains nascent.

Key Players:

=> Grifols Therapeutics, Genefit (Versantis), Martin Pharmaceuticals, Fresenius SE & Co. KGaA, Cellaion, Yaqrit Discovery Ltd, GNI Group Ltd among others.

Growth Forecast Projected:

The Global Acute on Chronic Liver Failure Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Acute on Chronic Liver Failure Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=acute-on-chronic-liver-failure-aclf-market

Key Segments:

➥ By Disease Type: Type-A ACLF, Type-B ACLF, Type-C ACLF
➥ By Therapy Type: Liver Transplantation, Supportive Care, Medications, Others
➥ By End User: Hospitals, Ambulatory Surgical Centers, Others

Regional Analysis for Acute on Chronic Liver Failure Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Acute on Chronic Liver Failure producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Acute on Chronic Liver Failure revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/acute-on-chronic-liver-failure-aclf-market?sb

FAQ

Q: What is the growth rate of the Acute on Chronic Liver Failure Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 6% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.